Get the Stockscreener App
12.32
4.10%
0.485
After Hours:
12.25
-0.075
-0.61%
Integra Lifesciences Holdings Corp stock is traded at $12.32, with a volume of 1.39M.
It is up +4.10% in the last 24 hours and down -23.06% over the past month.
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
See More
Previous Close:
$11.84
Open:
$11.69
24h Volume:
1.39M
Relative Volume:
1.19
Market Cap:
$958.55M
Revenue:
$1.64B
Net Income/Loss:
$-495.80M
P/E Ratio:
-1.9246
EPS:
-6.404
Net Cash Flow:
$-45.25M
1W Performance:
-8.91%
1M Performance:
-23.06%
6M Performance:
+14.65%
1Y Performance:
-20.28%
1-Day Range:
$11.66
$12.36
1-Week Range:
$11.57
$13.83
52-Week Range:
$8.70
$20.49
Integra Lifesciences Holdings Corp Stock (IART) Company Profile
Name
Integra Lifesciences Holdings Corp
Sector
Industry
Phone
(609) 275-0500
Address
1100 CAMPUS ROAD, PRINCETON, NJ
Compare IART vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IART
Integra Lifesciences Holdings Corp
|
12.32 | 958.55M | 1.64B | -495.80M | -45.25M | -6.404 |
ABT
Abbott Laboratories
|
102.51 | 177.38B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
96.59 | 123.55B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.08 | 117.79B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
46.01 | 66.68B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.09 | 51.93B | 6.30B | 1.07B | 1.09B | 1.8406 |
Integra Lifesciences Holdings Corp Stock (IART) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-26 | Initiated | UBS | Neutral |
| Jul-09-26 | Initiated | BMO Capital Markets | Market Perform |
| Jun-18-26 | Upgrade | Argus | Hold → Buy |
| May-28-26 | Upgrade | Citigroup | Sell → Neutral |
| Apr-15-26 | Downgrade | Argus | Buy → Hold |
| Mar-31-25 | Upgrade | Argus | Hold → Buy |
| Dec-02-24 | Initiated | Morgan Stanley | Underweight |
| Oct-07-24 | Upgrade | BTIG Research | Sell → Neutral |
| Jul-30-24 | Downgrade | BTIG Research | Neutral → Sell |
| Jul-30-24 | Downgrade | Citigroup | Neutral → Sell |
| May-07-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-03-24 | Upgrade | Citigroup | Sell → Neutral |
| Dec-05-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-14-23 | Initiated | CL King | Buy |
| Aug-24-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-12-23 | Upgrade | Jefferies | Hold → Buy |
| Jun-08-23 | Downgrade | Argus | Buy → Hold |
| May-24-23 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-25-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Downgrade | Truist | Buy → Hold |
| Dec-17-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-27-20 | Initiated | Citigroup | Neutral |
| Apr-03-20 | Initiated | SunTrust | Buy |
| Jan-07-20 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-19 | Initiated | SunTrust | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Aug-07-18 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jul-26-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jul-02-18 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-18 | Resumed | Cantor Fitzgerald | Neutral |
| Jan-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-09-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-30-17 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Oct-27-17 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-30-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jan-13-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jan-06-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-12-16 | Initiated | UBS | Buy |
View All
Integra Lifesciences Holdings Corp Stock (IART) Latest News
Integra: 3 Key Takeaways for Long-Term Investors - The Motley Fool
Integra LifeSciences (IART) Surpasses Q3 Earnings Estimates - Zacks Investment Research
Integra LifeSciences Reports Third Quarter 2026 Financial Results - GlobeNewswire Inc.
Precision Trading with Integra Lifesciences Holdings Corporation (IART) Risk Zones - Stock Traders Daily
Integra Announces Completion of Refinancing Transactions - GlobeNewswire
Press Release Distribution & Media Outreach Platform for PR Agencies - ACCESS Newswire
Will Flood Driven Guidance Cut Change Integra LifeSciences Stock Narrative - Simply Wall Street
Integra LifeSciences Holdings (IART) Prices 9.5% Notes, Is The Repair Story Still Undervalued? - Simply Wall Street
Integra LifeSciences to Showcase ENT Portfolio and Support New Clinical Research at AAO-HNSF Annual Meeting - Quiver Quantitative
Integra LifeSciences to Highlight ENT and Instruments - GlobeNewswire
New research on balloon treatment alongside surgery for chronic ear disease will be presented - Stock Titan
Truist cuts target for Integra LifeSciences stock to USD 15.00 - ad-hoc-news.de
Press Release Distribution & Media Outreach Platform for PR Agencies - ACCESS Newswire
Truist Securities Adjusts Integra LifeSciences Price Target to $15 From $19 - Yahoo Finance
INTEGRA LIFESCIENCES HOLDINGS CORPORATION IART INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 21.2% Share Drop - Business Wire
Integra LifeSciences (IART) 10K Form and Latest SEC Filings 2026 - MarketBeat
Integra Lifesciences Holdings Corp (IART) Shares Surge 4.0% -- W - GuruFocus
What Is Integra LifeSciences Holdings (IART) $450 Million Debt Deal Changing? - Simply Wall Street
Integra LifeSciences Holdings Corporation at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Integra LifeSciences Holdings Corporation (IART) Investors to Inquire about Securities Investigation - ACCESS Newswire
Integra LifeSciences (IART) Prices $450M Senior Secured Notes Ma - GuruFocus
Integra LifeSciences prices $450M senior secured notes at 9.5% - Investing.com
Integra LifeSciences Prices $450 Million of 9.500% Senior Secured Notes Due 2033 - Quiver Quantitative
Integra Announces Pricing of Senior Secured Notes - GlobeNewswire
$450 million in Integra LifeSciences notes carry a 9.5% rate - Stock Titan
Integra LifeSciences Holdings (IART) Resets Guidance As The Undervalued Narrative Faces A Fresh Test - Simply Wall Street
A Look at Integra Lifesciences Holdings Corp (IART) After 3.1% G - GuruFocus
Integra LifeSciences Holdings (IART) Cuts 2026 Revenue Outlook, Is The Stock Below Fair Value? - Yahoo Finance
Wells Fargo cut its target for Integra LifeSciences stock to USD 15.00 - AD HOC NEWS
Integra LifeSciences stock cuts guidance after Cincinnati flooding - AD HOC NEWS
BMO cuts target for Integra LifeSciences stock to USD 15 - AD HOC NEWS
INTEGRA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026 - GlobeNewswire
Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026 - GlobeNewswire
How Investors Are Reacting To Integra LifeSciences Holdings (IART) Full Year Revenue Cut - Simply Wall Street
Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026 - Yahoo Finance
INTEGRA LIFESCIENCES HOLDINGS CORPORATION INVESTIGATION: - GlobeNewswire
Flood Damage Prompts Integra LifeSciences To Revise 2026 Outlook - Benzinga
BMO cuts Integra LifeSciences stock price target on facility disruption - Investing.com
Integra LifeSciences (NASDAQ: IART) Investor Alert: Johnson - GlobeNewswire
Wells Fargo cuts Integra LifeSciences price target on lower revenue outlook - Investing.com
Is Integra Lifesciences Holdings Corp (IART) a Bargain After 21. - GuruFocus
Why Integra LifeSciences (IART) Stock Is Nosediving - Yahoo Finance
Integra LifeSciences (IART) Shares Plunge Nearly 21% Following Q - GuruFocus
Integra LifeSciences plunges 21% on preliminary Q3 results (IART:NASDAQ) - Seeking Alpha
Integra LifeSciences Q3FY26 Results: Guidance cut on flood impact - scanx.trade
Stock Market Midday, Oct. 2: Stocks Rally as Weak Jobs Data Cools Fed Rate Hike Bets - The Motley Fool
Integra LifeSciences Holdings Corporation Announces Launch Of $600 Million Senior Secured Term Loan B - marketscreener.com
Why is Integra LifeSciences stock tumbling today? - Investing.com
Integra LifeSciences stock tumbles after cutting 2026 outlook - Investing.com
Integra Lifesciences Holdings Corp Stock (IART) Financials Data
Revenue
Net Income
Cash Flow
EPS
Integra Lifesciences Holdings Corp Stock (IART) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Singh Harvinder | EVP & PRESIDENT, INTERNATIONAL |
Mar 10 '26 |
Option Exercise |
0.00 |
1,216 |
0 |
23,152 |
| Poul Mojdeh | President & CEO |
Jan 06 '26 |
Option Exercise |
0.00 |
1,390 |
0 |
1,390 |
| GRAVES JEFFREY A | Director |
Nov 05 '25 |
Buy |
11.35 |
9,000 |
102,150 |
41,086 |
| Singh Harvinder | EVP & PRESIDENT, INTERNATIONAL |
Oct 12 '25 |
Option Exercise |
0.00 |
11,965 |
0 |
25,217 |
3.55%
4.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):